论文部分内容阅读
目的:探讨水飞蓟宾胶囊联合恩替卡韦治疗慢性乙型肝炎合并脂肪肝的疗效。方法:收治慢性乙型肝炎合并脂肪肝患者60例,随机分为治疗组和对照组各30例,治疗组在常规治疗基础上予以恩替卡韦联合水飞蓟宾胶囊,对照组在常规治疗基础上予以恩替卡韦治疗,对比两组的疗效。结果:治疗组24周的生化学应答率显著高于对照组(P<0.05),血脂改善率优于对照组(P<0.05)。结论:水飞蓟宾胶囊联合恩替卡韦在慢乙肝合并脂肪肝的治疗中有较好的疗效。
Objective: To investigate the effect of silybin capsule combined with entecavir in treating chronic hepatitis B with fatty liver. Methods: Sixty patients with chronic hepatitis B and fatty liver were randomly divided into treatment group (n = 30) and control group (n = 30). The treatment group was given entecavir combined with silybin capsule on the basis of routine treatment. The control group was given on the basis of routine treatment Entecavir treatment, the efficacy of the two groups were compared. Results: The biochemical response rate of the 24-week treatment group was significantly higher than that of the control group (P <0.05), and the improvement rate of blood lipids was better than that of the control group (P <0.05). Conclusion: Silybin capsules combined with entecavir in the treatment of chronic hepatitis B with fatty liver has a good effect.